Orthogon Therapeutics

Executive Summary

Orthogon Therapeutics is a privately held biotech company headquartered in Cambridge, MA, founded in 2018. The company is pioneering small molecule therapeutics that target challenging protein-protein interactions (PPIs), leveraging a proprietary drug discovery platform integrating structural biology, biophysics, and artificial intelligence. Orthogon's initial focus is on developing the first-ever treatments for polyomavirus infections in immunocompromised patients, particularly transplant recipients, where current options are limited. While the company has not disclosed specific financials, its platform approach addresses historically undruggable targets and could have broad applicability beyond virology. The company remains in early-stage R&D, with no clinical-stage programs or partnerships publicly announced as of early 2026.

Upcoming Catalysts (preview)

• TBDLead optimization data for lead polyomavirus candidate40% success
• TBDSeries A financing announcement35% success
• TBDIND-enabling studies initiation30% success